1. Pink Sheet
  3. >>North America

Sunscreen TEA Advocates Want Help Scaling FDA’s ‘High Bar’ For OTC Monographs

 
• By Eileen Francis

FDA explains its “high bar” for GRASE for sunscreen TEAs during a public meeting on implementation of the Sunscreen Innovation Act. Industry and advocacy groups express concern that impediments to meeting OTC monograph safety standards will squelch sunscreen ingredient innovation.

FDA officials explain the agency’s “high bar” for adding ingredients to OTC monographs and the “heavy lift” that work requires, attempting to assuage the frustrations of proponents of making additional sunscreen ingredients available.

Representatives from the sunscreen industry and consumer advocacy groups and FDA officials attempted to find common ground during a Feb....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Best Laid Plans: A Chronology Of Post-Pandemic COVID-19 Vaccines

 
• By Bridget Silverman

Quick responses to late-breaking changes to US FDA COVID-19 vaccine policy kept Novavax's Nuvaxovid and Moderna's mNexspike close to expected approval timelines despite revised indications and new post-marketing trial commitments.

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 
• By Sarah Karlin-Smith

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.

GLP-1s In Crosshairs As Employers Worry About Health Costs – And Their Own Reliance On Rebates

 
• By Cathy Kelly

Business Group on Health annual employer survey highlights fast-growing Rx costs, led by the GLP-1 drugs, and payer strategies for controlling them. Policy prescriptions are unclear, though, since employers are loath to leave PBMs and nervous about pending changes to Medicare and Medicaid.